Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Sang Hyun Yoon; Ki Hyang Kim; Junjeong Choi; Gun Min Kim; Joo Hoon Kim; Hyo Song Kim; Young Nyun Park; Sun Young Rha

doi:10.4143/crt.2010.42.3.180

Articles

Page Path: HOME > Cancer Res Treat > Volume 42(3); 2010 > Article

Case Report Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis: Sang Hyun Yoon, M.D.¹, Ki Hyang Kim, M.D.¹, Junjeong Choi, M.D.², Gun Min Kim, M.D.¹, Joo Hoon Kim, M.D.¹, Hyo Song Kim, M.D.¹, Young Nyun Park, M.D., Ph.D.^2,3, Sun Young Rha, M.D., Ph.D.^1,3; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2010;42(3):180-184.
DOI: https://doi.org/10.4143/crt.2010.42.3.180
Published online: September 30, 2010

¹Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

²Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

³Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Correspondence: Sun Young Rha, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Tel: 82-2-2228-8050, Fax: 82-2-362-5592, rha7655@yuhs.ac

• Received: April 14, 2010 • Accepted: May 17, 2010

10,084 Views
67 Download
8 Crossref

Full Article

Download PDF

Abstract
Introduction
Case Report
Discussion
REFERENCES

Abstract

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Key words: Renal cell carcinoma, Sunitinib, Renal dialysis

Introduction

Long term dialysis is a risk factor for renal cell carcinoma (RCC) since the prevalence of RCC in hemodialysis or renal transplant patients is 40 to 100 times higher than that of the general population. The kidney and urinary tract organs are susceptible to systemic carcinogenic effects extending from biochemical and immunologic changes that occur with renal pathologies, resulting in loss of proper renal function (1-3).

In spite of increasing numbers of RCC patients with renal impairment, most clinical trials do not include these patients and there is therefore little knowledge regarding systemic chemotherapy in end stage renal disease (ESRD) patients (4). Sunitinib is an oral tyrosine kinase inhibitor (TKI) targeting the vascular endothelial growth factor receptor and the platelet derived growth factor receptor. Given as first-line treatment in metastatic RCC, it has shown clinical activity in a phase III randomized trial and is the current standard treatment for metastatic RCC (5-8). It is usually administered as a once daily dose of 50 mg in a schedule of 4 weeks on and 2 weeks off. Sunitinib and its main metabolite, SU12662, are mainly eliminated in the feces and only 15 to 20% of the dose is cleared by kidney (9). The proper dose and schedule of sunitinib have yet to be established in patients with metastatic RCC on hemodialysis. In addition, long-term treatment outcome and tolerability of sunitinib in patients on hemodialysis have not been reported.

Here, we describe two patients with metastatic RCC on hemodialysis who were treated with intermittent doses of sunitinib in accordance with the patient's renal function.

Case Report

1. Patient

A 53-year old male underwent right nephrectomy for stage II (pT2N0M0) clear cell RCC in 1996. In 2004, a mass was detected in the right gluteus muscle which proved to be metastatic RCC on biopsy. He underwent radiation therapy after which he was confirmed as having no residual lesions. Thereafter he developed impaired renal function with serum blood urea nitrogen (BUN) 85 mg/dL and creatinine 7.5 mg/dL. Hemodialysis was begun three times a week in 2004. In 2005, right lung wedge resection was performed due to a metastatic lesion (Fig. 1A) and he was free of recurrent or metastatic lesions until January 2009 when multiple lung metastases developed. The prognostic risk category of the patient was intermediate as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model, with Karnofsky performance status 90%, serum hemoglobin 10.7 mg/dL, serum corrected calcium 10.6 mg/dL, lactate dehydrogenase (LDH) 168 IU/L. Baseline computed tomography (CT) scan of the chest showed right hilar lymph node enlargement, a chest wall mass and multiple lung metastases. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 times a week) from 15 January 2009. The best response was partial response (PR) with 30% size reduction from baseline (Fig. 2). At the time of reporting, April 2010, the patient was tolerating sunitinib relatively well and the progression-free survival (PFS) was 16 months. Most adverse effects observed were neuropathy, facial edema, skin rash, yellowish skin pigmentation, diarrhea, thrombocytopenia, anemia and leucopenia. All of these toxicities were manageable (grade 1). Blood pressure was well controlled with standard anti-hypertensive medications and there was no evidence of hypothyroidism. Although, the patient has been tolerating sunitinib, complications such as increasing chronic fatigue and general weakness, resulting in decreased general performance and activity, were apparent after 1 year of treatment.

2. Patient

A 67-year old female was diagnosed with ESRD due to hypertension and started hemodialysis in May 2006. After 1 month of hemodialysis, a left kidney tumor developed and she underwent nephrectomy for stage I (pT1N0M0) clear cell RCC. In May 2009, multiple metastatic lesions began to develop in her right auricular, right forearm, right axillary, and right scapular areas. She also developed additional lymph nodes at her right hilum and multiple metastatic lesions in her lungs and bones. Biopsies of her right auricular and forearm masses showed metastatic clear cell RCC (Fig. 1B). The prognostic risk category of the patient was intermediate as defined by the MSKCC risk model with Karnofsky performance status 90%, serum hemoglobin 11.4 mg/dL, serum corrected calcium 10.7 mg/dL, LDH 229 IU/L. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (4 times a week) from November 2009. The best response was PR with 34% size reduction from baseline after 4 months of treatment (Fig. 3). Adverse events such as aggravation of hypertension or hypothyroidism did not occur. At the time of reporting, April 2010, she was tolerating intermittent sunitinib well and the PFS was 6 months.

Discussion

We compared our cases with 3 previously reported cases (in 2 reports) in which metastatic RCC patients on hemodialysis were treated with sunitinib (Table 1) (10,11). All cases, including ours, involved clear cell type RCC. The prognostic risk categories of the patients in our report were intermediate as defined by the MSKCC risk model, but there were no such descriptions in the previous reports. There were similarities in the responses and toxicities of the previous reports and ours. However, the dosage methods were different in each report. Sunitinib was administered daily in 6-week cycles: administration for 4 weeks followed by 2 weeks off treatment in both previous reports. The sunitinib dose was 50 mg daily irrespective of hemodialysis in Park's report (11). In contrast, Zastrow et al. (10) started with a sunitinib dose of 25 mg daily, irrespective of hemodialysis, and increased to 37.5 mg and 50 mg according to the patients' tolerance. Overall responses were complete response (CR) by the patient in Park's report (11), and CR by one patient and stable disease by the other patient in Zastrow et al.'s report (10). However, the dose intensity in these two reports was similar to that used with non-ESRD patients, and it seemed that higher cumulative doses of the sunitinib resulted in better responses. Our sunitnib dose intensity, 50 mg after each hemodialysis session (3 or 4 times a week), was much lower than the dose intensities of the previous reports. Both patients had achieved PR at the time of reporting and we expect to see improvements of their outcomes as the cumulative dose increases.

During the planning stages of our sunitinib therapy, we were unable to find any guidelines for treatment of hemodialysis patients. We therefore decided to treat patients with the dosage method described above on the basis of three rationale: 1) the half-life of sunitinib is 40 to 60 hours; 2) reduced doses of usual cytotoxic drugs are used in hemodialysis patients (4); 3) long-term tolerability sustains durable response, especially with TKI treatments in RCC. Both subjects tolerated the treatment without interruptions of sunitinib. Significantly, the time to response (1 year) was longer than that seen with other cytotoxic drugs or conventional sunitinib. Thus, it is important to keep patients tolerating treatment in order to maintain prolonged response. Furthermore, Hong et al. (12) reported that sunitinib toxicities accumulated and were apparent after approximately 1 year of sunitinib treatment in more than 50% of patients. Therefore, standard dose long-term sunitinib treatment might aggravate underlying hypertension and general weakness of ESRD patients. It is thus important to find an effective dosage associated with minimal toxicity. In this regard, our dosage method would have the same efficacy in metastatic RCC patients on hemodialysis as previous reports and we suggest that it be widely adopted.

From our experiences with two patients, we suggest that the intermittent treatment mode used here could be an alternative option for treating metastatic RCC in the context of hemodialysis: fifty milligrams of sunitinib after each hemodialysis session.

REFERENCES

1. Keith DS, Torres VE, King BF, Zincki H, Farrow GM. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;4:1661–1669. PMID: 8011975Article PubMed
2. Hughson MD, Buchwald D, Fox M. Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. Arch Pathol Lab Med. 1986;110:592–601. PMID: 3521533PubMed
3. Peces R, Martinez-Ara J, Miguel JL, Arrieta J, Costero O, Gorriz JL, et al. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in predialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant. 2004;19:2789–2796. PMID: 15316098Article PubMed
4. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–1403. PMID: 20118214Article PubMed
5. Escudier B. Sorafenib in kidney cancer. Ann Oncol. 2007;18(Suppl 9):ix90–ix93. PMID: 17631603Article PubMed
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111. PMID: 18156031Article PubMed
7. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958–3964. PMID: 17761980Article PubMed
8. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883–1887. PMID: 17868732Article PubMed
9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35. PMID: 16314617Article PubMed
10. Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology. 2009;73:868–870. PMID: 19167044Article PubMed
11. Park CY. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anticancer Drugs. 2009;20:848–849. PMID: 19644356Article PubMed
12. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat. 2009;41:67–72. PMID: 19707503Article PubMed PMC PDF

Fig. 1

The pathologic features of recurred lesions. Metastatic lesion of lung in case 1 (H&E, ×200) (A). Metastatic lesion of forearm, skin in case 2 (H&E, ×400) (B).

Fig. 2

Response evaluation of the CT scans in case 1. Target lesions were right hilar lymph node with 41.7 mm (A) and chest wall mass with 40.9 mm (G). Non-target lesions were multiple lung masses (D). After 2 months of treatment, multiple lung lesions started to decrease (B, E, H). After 13 months of treatment, hilar lymph node decreased to 30.7 mm (C) and chest wall mass became 26.7 mm (I) with 30% of size reduction. Non-target lesions also decreased without any new lesions (F).

Fig. 3

Response evaluation of the CT scans and bone scans in case 2. Target lesion was right hilar lymph node with 34.4 mm (A). Non-target lesions were multiple lesions of lung (C) and bone (E). After 4 months of treatment, the target lesion decreased to 22.6 mm (B), which was 34% reduction, and non-target lesions also decreased (D, F).

Table 1

Reports of sunitinib treatment in metastatic renal cell carcinoma (RCC) patients on hemodialysis

^*Memorial Sloan-Kettering Cancer Center, ^†progression-free survival, ^‡complete response, ^§stable disease, ^∥hemodialysis, ^¶partial response.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
Elodie Klajer, Louis Garnier, Morgan Goujon, Friederike Schlurmann-Constans, Benoite Mery, Thierry Nguyen Tan Hon, Guillaume Mouillet, Fabien Calcagno, Antoine Thiery-Vuillemin
Seminars in Oncology.2020; 47(2-3): 103. CrossRef
Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini, Camillo Porta
EMJ Nephrology.2016; : 66. CrossRef
Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro
Current Urology Reports.2015;[Epub] CrossRef
Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of Experience
Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk, Cezary Szczylik
Future Oncology.2015; 11(16): 2267. CrossRef
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong-Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha
European Journal of Cancer.2014; 50(4): 746. CrossRef
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte, Pierre I. Karakiewicz
Cancer Treatment Reviews.2013; 39(4): 388. CrossRef
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moscetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cin
BJU International.2012; 110(5): 692. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Cancer Res Treat. 2010;42(3):180-184. Published online September 30, 2010

DOI: https://doi.org/10.4143/crt.2010.42.3.180

XML Download

Figure

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Fig. 1 The pathologic features of recurred lesions. Metastatic lesion of lung in case 1 (H&E, ×200) (A). Metastatic lesion of forearm, skin in case 2 (H&E, ×400) (B).

Fig. 2 Response evaluation of the CT scans in case 1. Target lesions were right hilar lymph node with 41.7 mm (A) and chest wall mass with 40.9 mm (G). Non-target lesions were multiple lung masses (D). After 2 months of treatment, multiple lung lesions started to decrease (B, E, H). After 13 months of treatment, hilar lymph node decreased to 30.7 mm (C) and chest wall mass became 26.7 mm (I) with 30% of size reduction. Non-target lesions also decreased without any new lesions (F).

Fig. 3 Response evaluation of the CT scans and bone scans in case 2. Target lesion was right hilar lymph node with 34.4 mm (A). Non-target lesions were multiple lesions of lung (C) and bone (E). After 4 months of treatment, the target lesion decreased to 22.6 mm (B), which was 34% reduction, and non-target lesions also decreased (D, F).

Fig. 1

Fig. 2

Fig. 3

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Table 1

Reports of sunitinib treatment in metastatic renal cell carcinoma (RCC) patients on hemodialysis

^*Memorial Sloan-Kettering Cancer Center, ^†progression-free survival, ^‡complete response, ^§stable disease, ^∥hemodialysis, ^¶partial response.

Table 1 Reports of sunitinib treatment in metastatic renal cell carcinoma (RCC) patients on hemodialysis

^*Memorial Sloan-Kettering Cancer Center, ^†progression-free survival, ^‡complete response, ^§stable disease, ^∥hemodialysis, ^¶partial response.